Avicanna Inc. (TSX:AVCN)

Avicanna is a life sciences company focused on advancement and commercialization of evidence-based cannabinoid products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D & clinical development that has led to the commercialization of 30+ products across various market segments:

• Medical Cannabis & Wellness Products (RHO Phyto™): The formulary offers a diverse range of proprietary formulations including oral, sublingual, topical, & transdermal deliveries with varying ratios of cannabinoids and is supported with ongoing patient, and medical community education. RHO Phyto is a leading medical brand in Canada and is currently available nationwide to patients across several medical channels and continues to expand into new international markets.

• Pharmaceutical Preparations and Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has an extensive pipeline of indication-specific, patent-pending drug candidates in various stages of clinical development and commercialization. These drug candidates aim to address unmet medical needs in dermatology, chronic pain, and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox™) is approved in Colombia and is in registration in other South American markets.

• MyMedi.ca Medical Cannabis Care: MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the patient journey. MyMedi.ca is operated by Northern Green Canada Inc., and features a diverse portfolio of products and pharmacist-led patient support programs. It also provides specialty services to distinct patient groups such as veterans and collaborates with public and private providers for adjudication and reimbursement. MyMedi.ca provides educational resources to facilitate the incorporation of medical cannabis into health care regimens.